Biogen (BIIB), Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in AD Due to Futility

March 21, 2019 7:01 AM
Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced the decision to discontinue the global Phase 3 trials ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Hot Corp. News Hot FDA News Management Comments Trading Halts

Next Articles